| Literature DB >> 32213712 |
Elisabeth Zechendorf1, Caroline E O'Riordan2, Lara Stiehler1, Natalie Wischmeyer1, Fausto Chiazza3, Debora Collotta3, Bernd Denecke4, Sabrina Ernst5, Gerhard Müller-Newen5, Sina M Coldewey6,7, Bianka Wissuwa6,7, Massimo Collino3, Tim-Philipp Simon1, Tobias Schuerholz8, Christian Stoppe1, Gernot Marx1, Christoph Thiemermann2, Lukas Martin1.
Abstract
Septic cardiomyopathy is a life-threatening organ dysfunction caused by sepsis. Ribonuclease 1 (RNase 1) belongs to a group of host-defense peptides that specifically cleave extracellular RNA (eRNA). The activity of RNase 1 is inhibited by ribonuclease-inhibitor 1 (RNH1). However, the role of RNase 1 in septic cardiomyopathy and associated cardiac apoptosis is completely unknown. Here, we show that sepsis resulted in a significant increase in RNH1 and eRNA serum levels compared with those of healthy subjects. Treatment with RNase 1 resulted in a significant decrease of apoptosis, induced by the intrinsic pathway, and TNF expression in murine cardiomyocytes exposed to either necrotic cardiomyocytes or serum of septic patients for 16 hours. Additionally, treatment of septic mice with RNase 1 resulted in a reduction in cardiac apoptosis, TNF expression, and septic cardiomyopathy. These data demonstrate that eRNA plays a crucial role in the pathophysiology of the organ (cardiac) dysfunction in sepsis and that RNase and RNH1 may be new therapeutic targets and/or strategies to reduce the cardiac injury and dysfunction caused by sepsis.Entities:
Keywords: Anesthesiology; Immunology; Inflammation; Innate immunity; Pharmacology
Mesh:
Substances:
Year: 2020 PMID: 32213712 PMCID: PMC7205433 DOI: 10.1172/jci.insight.131571
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708